Danaher Co. (DHR) Stock Rating Upgraded by Vetr Inc.

Danaher Co. (NYSE:DHR) was upgraded by equities researchers at Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Thursday. The brokerage presently has a $94.18 price objective on the conglomerate’s stock. Vetr‘s price target indicates a potential upside of 13.62% from the stock’s previous close.

Several other research analysts have also commented on the stock. Deutsche Bank AG restated a “buy” rating and set a $88.00 price target on shares of Danaher in a research note on Wednesday, January 18th. Royal Bank of Canada set a $84.00 price target on shares of Danaher and gave the stock a “hold” rating in a research note on Monday, January 2nd. Credit Suisse Group AG upgraded shares of Danaher from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $80.00 to $93.00 in a research note on Wednesday, February 1st. Zacks Investment Research lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Thursday, December 29th. Finally, Citigroup Inc upgraded shares of Danaher from a “neutral” rating to a “buy” rating and set a $98.00 price target on the stock in a research note on Friday, February 24th. Three equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $93.69.

Analyst Recommendations for Danaher (NYSE:DHR)

Shares of Danaher (NYSE:DHR) traded down 4.11% during trading on Thursday, hitting $82.89. The company’s stock had a trading volume of 8,816,984 shares. Danaher has a 52 week low of $72.34 and a 52 week high of $102.79. The firm’s 50 day moving average price is $86.21 and its 200-day moving average price is $81.56. The company has a market cap of $57.47 billion, a PE ratio of 22.70 and a beta of 1.00.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Thursday, April 20th. The conglomerate reported $0.85 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.84 by $0.01. Danaher had a net margin of 12.84% and a return on equity of 12.38%. The company had revenue of $4.21 billion for the quarter, compared to analyst estimates of $4.17 billion. During the same quarter in the prior year, the business posted $1.08 EPS. Danaher’s quarterly revenue was up 7.2% on a year-over-year basis. On average, analysts predict that Danaher will post $3.95 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, April 28th. Shareholders of record on Friday, March 31st will be issued a $0.14 dividend. The ex-dividend date of this dividend is Wednesday, March 29th. This is an increase from Danaher’s previous quarterly dividend of $0.13. This represents a $0.56 dividend on an annualized basis and a yield of 0.68%. Danaher’s dividend payout ratio is 13.66%.

ILLEGAL ACTIVITY NOTICE: “Danaher Co. (DHR) Stock Rating Upgraded by Vetr Inc.” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.wkrb13.com/markets/2065736/danaher-co-dhr-stock-rating-upgraded-by-vetr-inc.html.

In other Danaher news, SVP Robert S. Lutz sold 37,870 shares of the stock in a transaction on Friday, February 24th. The shares were sold at an average price of $85.60, for a total value of $3,241,672.00. Following the completion of the sale, the senior vice president now directly owns 27,475 shares of the company’s stock, valued at approximately $2,351,860. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Brian W. Ellis sold 983 shares of the stock in a transaction on Tuesday, February 28th. The shares were sold at an average price of $86.00, for a total transaction of $84,538.00. Following the completion of the sale, the insider now directly owns 6,174 shares of the company’s stock, valued at $530,964. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,009 shares of company stock valued at $5,106,487. Insiders own 12.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of the stock. BTC Capital Management Inc. increased its stake in shares of Danaher by 4.2% in the third quarter. BTC Capital Management Inc. now owns 58,045 shares of the conglomerate’s stock worth $4,546,000 after buying an additional 2,344 shares during the period. HL Financial Services LLC increased its stake in shares of Danaher by 21.2% in the third quarter. HL Financial Services LLC now owns 7,941 shares of the conglomerate’s stock worth $622,000 after buying an additional 1,391 shares during the period. Conning Inc. increased its stake in shares of Danaher by 0.4% in the third quarter. Conning Inc. now owns 49,078 shares of the conglomerate’s stock worth $3,847,000 after buying an additional 210 shares during the period. OLD Second National Bank of Aurora increased its stake in shares of Danaher by 28.6% in the third quarter. OLD Second National Bank of Aurora now owns 16,859 shares of the conglomerate’s stock worth $1,322,000 after buying an additional 3,754 shares during the period. Finally, Tirschwell & Loewy Inc. increased its stake in shares of Danaher by 0.8% in the third quarter. Tirschwell & Loewy Inc. now owns 248,541 shares of the conglomerate’s stock worth $19,483,000 after buying an additional 1,945 shares during the period. 76.14% of the stock is owned by hedge funds and other institutional investors.

Danaher Company Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

5 Day Chart for NYSE:DHR

To view Vetr’s full report, visit Vetr’s official website.

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2065736/danaher-co-dhr-stock-rating-upgraded-by-vetr-inc.html

Receive News & Ratings for Danaher Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Co. and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.